Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “cells”

914 pharma patents match "cells" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 914
Index total 30,257
Page 31 / 39

Quick answer

This filtered view shows 914 pharmaceutical patents matching "cells" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

914 results for “cells” · 30,257 patents in full index Clear search

  1. US 7659118

    Multipotent adult stem cells

    Regents of the University of Minnesota · Granted Feb 9, 2010 · Expires Feb 4, 2030

    granted

  2. US 7618623

    Hybrid adeno-retroviral vector for the transfection of cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Nov 17, 2009 · Expires Nov 12, 2029

    granted

  3. US 7611885

    Pharmaceutically compatible method for purifying intact bacterial minicells

    EnGeneIC Molecular Delivery Pty Ltd · Granted Nov 3, 2009 · Expires Oct 29, 2029

    granted

  4. US 7608257

    Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

    ONCOLYTICS BIOTECH INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

    granted

  5. US 7585622

    Increasing the proliferative capacity of cells using telomerase reverse transcriptase

    The Regents of the University of Colorado · Granted Sep 8, 2009 · Expires Sep 3, 2029

    granted

  6. US 7579188

    Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

    The Regents of the University of California · Granted Aug 25, 2009 · Expires Aug 20, 2029

    granted

  7. US 7576065

    Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2009 · Expires Aug 13, 2029

    granted

  8. US 7560105

    Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses

    Leids Universitair Medisch Centrum · Granted Jul 14, 2009 · Expires Jul 9, 2029

    granted

  9. US 7547546

    Progenitor cells from wharton's jelly of human umbilical cord

    Tissue Regeneration Therapeutics Inc. · Granted Jun 16, 2009 · Expires Jun 11, 2029

    granted

  10. US 7541034

    Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors

    The United States of America, as represented by the Department of Health and Human Services · Granted Jun 2, 2009 · Expires May 28, 2029

    granted

  11. US 7541429

    Comparative ligand mapping from MHC positive cells

    The Board of Regents of the University of Oklahoma · Granted Jun 2, 2009 · Expires May 28, 2029

    granted

  12. US 7527786

    Methods for inhibiting the growth of cancer cells expressing PSCA

    The Regents of the University of California · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  13. US 7507407

    Immunoliposomes that optimize internationalization into target cells

    The Regents of the University of California · Granted Mar 24, 2009 · Expires Mar 19, 2029

    granted

  14. US 7498170

    Bone precursor cells: compositions and methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 3, 2009 · Expires Feb 26, 2029

    granted

  15. US 7494666

    Cationic lipid compositions targeting angiogenic endothelial cells

    The Regents of the University of California · Granted Feb 24, 2009 · Expires Feb 19, 2029

    granted

  16. US 7491798

    Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins

    The United States of America, as represented by the Department of Health and Human Services · Granted Feb 17, 2009 · Expires Feb 12, 2029

    granted

  17. US 7479269

    Methods for selectively enriching TH1 and TH2 cells

    United States of America as represented by the Secretary of the Air Force · Granted Jan 20, 2009 · Expires Jan 15, 2029

    granted

  18. US 7468352

    Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors

    The United States of America, as represented by the Department of Health and Human Services · Granted Dec 23, 2008 · Expires Dec 18, 2028

    granted

  19. US 7442543

    Mammalian selenoprotein differentially expressed in tumor cells

    The United States of America, as represented by the Department of Health and Human Services · Granted Oct 28, 2008 · Expires Oct 23, 2028

    granted

  20. US 7431932

    Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

    ONCOLYTICS BIOTECH INC. · Granted Oct 7, 2008 · Expires Oct 2, 2028

    granted

  21. US 7431915

    Peptides whose uptake by cells is controllable

    The Regents of the University of California · Granted Oct 7, 2008 · Expires Oct 2, 2028

    granted

  22. US 7404954

    Methods of targeting agents to cells expressing the polymeric immunoglobulin receptor

    The Regents of the University of California · Granted Jul 29, 2008 · Expires Jul 24, 2028

    granted

  23. US 7378277

    Methods and compositions for transforming dendritic cells and activating T cells

    The United States of America, as represented by the Department of Health and Human Services · Granted May 27, 2008 · Expires May 22, 2028

    granted

  24. US 7364726

    Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine

    The Regents of the University of California · Granted Apr 29, 2008 · Expires Apr 24, 2028

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.